| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 693.4 | 650.3 | 611.8 |
| Other income | 13.8 | 15.1 | 8.2 |
| Total income | 707.2 | 665.4 | 620.0 |
| Profit before exceptional items & tax | 25.0 | 33.2 | 11.9 |
| Exceptional items | 0.0 | -31.9 | 0.0 |
| Profit before tax | 25.0 | 1.2 | 11.9 |
| Net profit | 16.5 | 4.0 | 6.0 |
| Operating margin | 3.5% | 0.2% | 1.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +175.00% |
|---|---|
| Net profit, quarter on quarter | +312.50% |
| Revenue, year on year | +13.30% |
| Operating profit, year on year | +202.70% |
| Operating profit, quarter on quarter | -38.10% |
BSE results filing, NSE: HCG. Figures extracted from the filing.
Healthcare Global Enterprises Ltd: key numbers
- Share price
- ₹698.65
- Market cap
- ₹10,431 Cr
- Revenue (annual)
- ₹2,545 Cr
- Net profit (annual)
- ₹13.76 Cr
- P/E (TTM)
- 457.5×Sector 57.8×
- Promoter holding
- 64.21%+0.00% QoQ
- FII holding
- 2.73%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Healthcare Global Enterprises Ltd
All →Healthcare Global Enterprises Annual General Meeting
HealthCare Global Enterprises held its 28th Annual General Meeting on September 18, 2026, via video conferencing to transact business items listed in the notice.
Healthcare Global Enterprises Employee Stock Options
HealthCare Global Enterprises Limited granted 64,46,843 employee stock options under its ESOS 2026 scheme. The grant carries an exercise price of INR 495 per share.
Healthcare Global Enterprises Earnings Call Transcript: Key Takeaways
HCG reported a strong Q1FY27 with 13% YoY revenue growth and 20% EBITDA growth, driven by volume and improved payor mix.
Healthcare Global Enterprises Investor Presentation: Key Takeaways
HCG reported strong Q1 FY27 results with 13% YoY revenue growth and 20% Adjusted EBITDA growth. Strategic focus on oncology and capacity expansion through a new North Bengaluru facility.
Healthcare Global Enterprises Earnings Call: Key Takeaways
HCG delivered strong FY26 performance with 15% revenue growth and margin expansion. Strategy focuses on oncology core through the sale of fertility unit Milann and brownfield expansion.
Healthcare Global Enterprises Earnings Call: Key Takeaways
HCG delivered strong FY26 results with 15% revenue growth and margin expansion to 18.5%, driven by operational leverage and clinical excellence.